Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

Abstract: The invention relates to a mixture comprising or consisting of: (a) one or more compounds of Formula 1: where the symbols in the compound or each compound of Formula 1 are defined as follows: m=0, 1, 2 or 3, p=0, 1 or 2, n=0, 1 or 2, where, when n=1 or 2, R1 and R2 in pairs are each H or together are another chemical bond, where, when m=1, 2 or 3, each X independently of the others is OH, O-alkyl or O-acyl, and where, when p=1 or 2, each Y independently of the others is OH, O-alkyl or O-acyl, and R3=H or alkyl, R3=H also representing the corresponding cosmetically or pharmaceutically acceptable salts and solvates; and (b) one or more antidandruff agents.

Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprising a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.

Abstract: The present invention relates generally to weight loss compositions and more particularly to orally administrable weight loss compositions for supporting weight loss in a subject in need thereof. Specifically, the present invention relates to compositions and methods comprising various combinations of orlistat and substances selected from methylxanthines, extracts of Morus sp., chromium polynicotinate, hydroxycitric acid or derivatives of hydroxycitric acid, flavanols, and yohimbine or derivatives of yohimbine.

Abstract: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.

Abstract: The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.

Abstract: The present invention provides a novel compound represented by the formula (I): wherein R1 and R2 are as defined in the specification, or a salt thereof, which is useful as a reagent (radiotracer) for VAChT mapping and the like, and can be used for positron emission tomography (PET), and a production method of the compound. Moreover, the present invention provides a diagnostic reagent for diagnosing cholinergic neurodegenerative disorders (e.g., Alzheimer's disease, memory disorder, learning disorder, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgia, Parkinson's disease and the like) and the like, which contains the aforementioned compound.

Abstract: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.

Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprision a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.

Abstract: The invention refers to a concentrate, in particular for the film preservation, a coating system as well as especial employment of a combination of active ingredients in the film preservation or as preservative. The concentrate contains chlorothalonile as well as one or more triazole(s) and/or isothiazolone(s).

Abstract: The present invention provides chromium compounds, specifically chromium dinicocysteinate, which possess the ability to improve insulin sensitization, glucose tolerance, bioavailability, efficacy, and safety, and methods for their use.

Abstract: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity of a user for the purpose of dissolving over a prolonged period of time and thereby delivering an essential oil component therein. In certain embodiments, the sustained release dosage form includes a beneficial agent and, therefore, not only provides for the prolonged delivery of an essential oil component to an oral cavity, but also provides for the sustained release of a beneficial agent thereto. In certain embodiments, the sustained release dosage form includes a biocompatible, water-insoluble polymer, e.g.

Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

Abstract: There are described mononuclear copper complexes having anti-inflammatory activity. The complexes include copper complexes of indomethacin. There are also provided methods for the prophylaxis or treatment of inflammation comprising administering such complexes to a mammalian subject.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of cancer, which contains, as an active ingredient, a pyridylpyridazine compound or a transition metal complex thereof. As described above, the pyridylpyridazine compounds according to the present invention and the transition metal complexes thereof have anticancer activity and can be easily prepared at low cost. Thus, these compounds are useful as anticancer agents against various cancers, including lung cancer, adenocarcinoma, skin cancer, colon cancer, uterine cancer and brain cancer, which are expressed due to immune system abnormality.

Abstract: This invention relates to therapies for diseases involving splicing defects, such as spinal muscular atrophy (SMA), and methods to identify compounds for treating this disease. The invention specifically provides for therapies comprised of small molecule compounds identified by cell-based high-throughput screening assays. These assays utilize engineered splicing constructs that fuse pre-mRNA fragments to a reporter gene. The fragments contain exons and at least one intron of a gene mutated in such a way to cause disease. Additionally, the invention provides for methods to monitor the effects of drugs on splicing and gene expression in vivo, in transgenic animals.

Abstract: Disclosed herein is a composition comprising a non-dusting copper pyrithione dispersion comprising small solid particles of copper pyrithione dispersed in a liquid dispersant, said solid particles having a particle size within a range of from about 0.1 to about 10 microns and a median particle size of from 0.2 to less than 0.5 microns. The dispersion is suitably employed as an antifouling additive for marine paints without risking worker exposure to copper pyrithione dust. Paints containing the small particle copper pyrithione exhibit improved antifouling performance in cold water, as compared to paint containing larger particle copper pyrithione.

Abstract: The present invention relates to an antimicrobial composition having antibacterial and antifungal properties and to an air filter manufactured using the composition. The filter of the present invention, comprising a filtration media treated with the antimicrobial composition having antibacterial and antifungal properties, has excellent antibacterial and antifungal properties, and thus can prevent the bacteria and fungi filtered by the filter from propagating in the filter.

Abstract: The invention provides several molybdenum (II) complexes (see classes I and II, FIG. 1) as well as pharmaceutical compositions comprising these compounds, that are useful for treating cancer and describes synthetic methods and intermediates useful for preparing the compounds.

Abstract: The invention relates to a coating material for protection against microorganism invasion on surfaces which are exposed to the effects of damp or water. The coating material has either a pH-value of at least 11.0 or is provide with a base material for the coating whereby the pH-value is at least 11. The coating material is characterized in that it contains a biocide which bonds to solid particles in a carrier material and is released in a delayed manner therefrom.

Abstract: The present invention is directed to an antimicrobial composition, comprising pyrithione or a pyrithione complex; and a zinc or copper or silver source selected from the group consisting of zinc or copper or silver salts, oxides, hydroxides, sulfates, chlorides, metals, and combinations thereof; wherein the weight ratio of the zinc or copper or silver source to the pyrithione or the pyrithione complex is in the range from about 1:300 to about 50:1, and wherein the antimicrobial composition has an enhanced biocidal effect against a variety of free-living microorganisms or biofilms. Also disclosed is a method of inhibiting the growth of free-living microorganisms or biofilm utilizing the above antimicrobial composition, as well as use of such antimicrobial compositions in various products including fuels, fluids, lubricants, coatings, adhesives, sealants, elastomers, soaps, cosmetics, plastic or woven or non-woven fibers, pharmaceuticals, and as preservatives for the above products.

Abstract: Highly concentrated, water-based dispersions of certain lipophilic and/or hydrophobic antimicrobially active materials are stabilized to a surprising degree by a surfactant combination including a nonionic acrylic graft copolymer surfactant and a alkoxylated polyarylphenol phosphate ester surfactant. The active materials may be present in dispersion concentrates of the present invention singly or in useful combinations. The active materials are selected from the group of fungicides and bactericides consisting of 1,2-benzisothiazol-3(2H)-one; 2-octyl-2H-isothiazol-3-one; 5-chloro-2-methyl-2H-isothiazol-3 -one; 2-methyl-2H-isothiazol-3-one; pyrithione zinc; 3-iodo-2-propynyl butylcarbamate; 2-methylthio-4-ethylamino-6-tert-butylamino-s-triazine; and 3-(4-isopropylphenyl)-1,1-dimethylurea, and mixtures thereof. The dispersion concentrates may be efficiently shipped and stored, and subsequently diluted with water to produce less concentrated dispersions when desired.

Abstract: A method for inhibiting microbial growth comprises administering an effective amount of a silver complex of a N-heterocyclic amine. A method for treating cancer cells or a method for imaging one or more tissues of a patient includes administering an effective amount of a complex of a N-heterocyclic amine and a radioactive metal. N-heterocyclic carbenes of the present invention may be represented by formula (I) wherein Z is a heterocyclic group, and R1 and R2 are, independently or in combination, hydrogen or a C1-C12 organic group selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heterocyclic, and alkoxy groups and substituted derivatives thereof.

Abstract: The invention provides a hair and/or scalp care composition comprising a terpenoid compound of formula (I), (II) or (III) in which R1 to R11 are each, independently, —H, —F, —Cl, —Br, —I, —OH, lower alkyl (e.g. C1-6 alkyl) or lower alkoxy (e.g. C1-6 alkoxy).

Abstract: Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.

Abstract: The present invention relates to pharmaceutical compositions comprising an antipsychotic agent in combination with a chromium salt, which are used for minimizing side effects in a patient taking an antipsychotic agent.

Abstract: Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal “resident” micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both “transient” and “resident” micro-organisms.

Abstract: The invention provides a hair and/or scalp care composition which is a shampoo composition, comprising an anionic cleansing surfactant in an amount of from 5 to 30 wt % and visnadin. The invention also provides a hair and/or scalp care composition which is a conditioner composition, comprising a cationic conditioning surfactant in an amount of from 0.01 to 10 wt % and visnadin. The invention also a method of treating and/or preventing inflammatory skin conditions such as the scalp skin itching and flaking associated with dandruff, which method comprises topically applying a composition according to the invention to the hair and/or skin, preferably to the hair and/or scalp.

Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.

Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.

Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).

Abstract: The absolute configuration of a chiral compound is determined by (i) coordinating the chiral compound to a metalloporphyrin having a carbon chain-crosslinked porphyrin dimer structure in which one of the two porphyrin rings has at least one ethyl or substituent bulkier than ethyl at at least one of the second peripheral carbon atoms from the carbon atom at the carbon chain crosslink site, and (ii) analyzing the resultant coordination compound by circular dichroism spectrophotometry to determine the absolute configuration of the asymmetric carbon based on the sign of the Cotton effect. The chiral compound has an asymmetric carbon bonded to a basic group capable of coordinating to the metal of the other porphyrin ring of the metalloporphyrin dimer or an asymmetric carbon atom adjacent to the carbon atom bonded to the basic group.

Abstract: Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.

Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.

Abstract: Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of an agent which reduces serum insulin levels.

Abstract: The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.

Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.

Abstract: Lanthanum compounds are provided having general formulas (I) Rni+Yin? and (II) Rb+Yb? which may be used as medicaments in the prophylaxis and/or treatment of cancer diseases.

Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.

Abstract: A dihydroxy(3-pyridyl)borane compound of the formula (1): wherein R1 represents a hydrogen atom, halogen atom or alkoxycarbonylamino group; R2 represents a hydrogen atom, halogen atom, alkyl group or fluoroalkyl group; with the proviso that the case wherein both R1 and R2 are hydrogen atoms is excepted.

Abstract: Disclosed are topical compositions for the treatment of microbial infections on the skin or scalp which include a polyvalent metal salt of pyrithione and include a metal ion source. Also disclosed are methods for treating microbial infections of the skin or scalp using such compositions.

Abstract: The invention relates to a compound of the general formula (I) where R1, R2, R3, R4, R1?, R2?, R3? and R4? are independently of one another hydrogen, C1–C15-alkyl, C2–C15-alkenyl, C2–C15-alkinyl, C3–C16-cycloalkyl, C3–C16-cycloalkenyl, aryl or a heterocyclus which in each case can be substituted or unsubstituted, Y is a physiologically compatible anion, and n is 1 or 2, as well as its application to the prophylaxis and/or tretment of cancer illnesses.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: Ruthenium (II) compounds of the formula: wherein: R1 is —CO2CH3; R2, R3, R4, R5 and R6 independently represent H, alkyl, cylcoalkyl, —CO2R?, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R? represents alkyl, cylcoalkyl, aryl or alkaryl; X is halo, H2O, (R?)(R?)SO, R?CO2? or (R?)(R?)C?O, where R? represents alkyl, cylcoalkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C? is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently R11—CN, where R? represents alkyl or cycloalkyl; or B is halo and A is 4-substitued pyridine; or p is 0, A is NR7R8 and B is NR9R10wherein R7, R8, R9 and R10 independently represent H, or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR7 and B is NR9R10, wherein R7, R9 and R10 are as previously defined, and A a

Abstract: The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging ?-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.

Abstract: A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 ?g of chromium and between 25 ?g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.